tbuckley/cabot-search huggingface dataset:
Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8–Negative Castleman Disease
Authors: Xiaolong Alan Zhou, Young Kwang Chae, Francis Joseph Giles
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Use of radiotherapy for seminoma patients with low-volume infradiaphragmatic nodal disease.
Authors: Swetha Sridharan, Peter W. M. Chung, Michael A. Jewett, Eshetu Atenafu, Philippe Bedard, Malcolm J. Moore, Padraig Richard Warde
Journal: Journal of Clinical Oncology (2013)

335 Background: Radiation therapy (RT) is established as standard management in testicular seminoma patients with low volume (&lt; 5cm in maximum diameter) retroperitoneal lymphadenopathy. Increasingly multi-agent chemotherapy (CT) is being recommended as first line therapy with its attendant toxicity. To further examine this issue, we reviewed the outcomes for such patients managed at our institution. Methods: After ethics board approval, data on 106 patients identified from a prospectively maintained institutional database with low volume retroperitoneal disease (&lt;5cm) were retrospectively reviewed. All patients were treated between 1995-2010 and had either relapsed Stage I disease on surveillance (59 pts) or Stage IIA/B at diagnosis (47 pts). Fifty eight patients had nodal disease of &lt;2cm (57 treated with RT, 1 with CT), and 48 had disease 2-5cm (30 treated with RT, 18 with CT). Median age was 37 years (range 24-83). The preferred treatment policy was to use RT when possible (25 Gy in 20 fractions to para-aortic and pelvis with 10 Gy boost to gross disease). Reasons for using chemotherapy included multiple enlarged nodes with largest node at least 3cm (n=11), disease proximity to renal hilum (n=4), inflammatory bowel disease (n=3) and patient choice (n=1). Seventeen-patients received EP (4 cycles) chemotherapy and 2 received BEP (3 cycles). Results: With a median follow-up of 73 months, there were no disease or treatment related deaths. The 5-year overall and relapse-free survival was 100% and 91%. Of 58 patients with LN size ≤ 2 cm, 5 relapsed, all initially treated with RT. Of 48 patients with LN size 2-5cm, 4 relapsed (3/30 treated with RT, 1/18 treated with CT). Acute toxicity (CTCAE v4 &gt;grade 1) was not observed in any patient treated with RT. In patients treated with CT, 7 developed G3/4 neutropenia, 2–grade 3 anemia, 2–grade 3 diarrhea, and 1 patient grade 3 weight loss. All relapsed patients were successfully salvaged by CT. Conclusions: A policy of routine use of RT in patients with low-volume nodal disease gives excellent results with &gt;75% of patients avoiding CT and only 6% of patients receiving both RT and CT. Retroperitoneal RT should be strongly considered as the treatment of choice in these patients.
Microsatellite instability status as a predictive marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer.
Authors: A. Zaanan, J. Flejou, J. Emile, P. Validire, C. Louvet, P. Rougier, A. De Gramont, F. Praz, J. Taïeb
Journal: Journal of Clinical Oncology (2011)

493 Background: The addition of oxaliplatin to 5-fluorouracil (5-FU; FOLFOX regimen) was demonstrated to improve the adjuvant treatment of stage III colon cancer. For patients with microsatellite instability (MSI) tumors, several studies suggested a lack of benefit from 5-FU adjuvant chemotherapy but very little data are available regarding FOLFOX adjuvant therapy. The aim of this study was to further assess the value of MSI status as a marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer. Methods: This multicentric retrospective study included 223 unselected patients with stage III colon cancer treated by FOLFOX adjuvant chemotherapy between 2003 and 2007. MSI status was determined by immunohistochemistry as the absence of MLH1, MSH2 or MSH6 expression. Disease-free survival (DFS) and relapse-free survival (RFS) were analyzed according to the MSI status using Kaplan Meier method and compared by log-rank test. Results: Twenty three tumors (10.3%) were MSI. The rate of 3-year DFS was 88.6% and 76.6% for MSI and MSS groups, respectively (HR=0.64; 95% CI, 0.25 to 1.60; P=0.34). The rate of 3-year RFS was 88.6% and 76.7% for MSI and MSS groups, respectively (HR=0.52; 95% CI, 0.20 to 1.30; P=0.18). Conclusions: A trend toward longer survival was observed for patients with MSI tumors compared with those with MSS tumors but the differences in survival were not significant. Interestingly, DFS at 3-years of patients with stage III MSI tumors treated by FOLFOX was higher in our series (88.6%) than in the largest study published for patients treated by 5-FU-based adjuvant chemotherapy (around 67.5%) or surgery alone (around 62.5%) (Sargent et al, JCO 2010). These observations suggest that adding oxaliplatin to 5-FU re-establishes a benefit of adjuvant treatment in the stage III MSI population. These results should be confirmed by analyzing materials of previously completed trials comparing FOLFOX to 5-FU such as the MOSAIC study. [Table: see text]
NCI-EDRN validation of salivary oral cancer biomarkers
Authors: D. T. Wong, J. Wang, J. Reiss, B. Zimmermann, H. Zhou, D. Elashoff, D. Morris, T. Randolph, Z. Feng, D. Chia
Journal: Journal of Clinical Oncology (2008)

6010 Background: We have previously developed a panel of 7 salivary mRNA as discriminatory biomarkers for oral cancer detection. The clinical behavior of these 7 oral cancer RNA biomarkers has been consistently demonstrated in three independent validation studies involving over 220 subjects. Concurrently, we have engaged in a Phase 2 biomarker validation project with the Biomarker Reference Laboratory (BRL) of the NCI's Early Detection Research Network (EDRN) at UCLA. Here we report the results of this Phase 2 validation study. Methods: Anonymized aliquots of saliva samples (32 oral cancer and 32 matched controls) were distributed to the EDRN and UCLA laboratories. Total RNA was isolated semi-automatically (KINGFISHER, Thermo Scientific) and the levels of seven salivary oral cancer transcriptomic biomarkers were quantified by a novel multiplex RT-PCR preamplification and subsequent singleplex real-time PCR for each of the 7 biomarkers. All reactions utilized the BioMek 3000 liquid handling platform in 96-well plates. Data (Ct numbers and relative copy numbers) were obtained and analyzed by statisticians at EDRN Data Management and Coordinating Center at the Fred Hutchinson Cancer Center. Area under the curves (AUC) for the combined markers were generated using a logistic regression model. Results: 1. Highly comparable results were generated in both EDRN and UCLA labs (Table). 2. Three genes for EDRN-BRL and all 7 from the UCLA lab were significantly elevated in oral cancer samples (p<0.05). 3. Area under the curve (AUC) of 0.85 and 0.86 were achieved by EDRN-BRL and the UCLA lab, respectively (7 markers combined). Conclusions: The predictive power and standardized measurement of these salivary oral cancer biomarkers were highly consistent and reproducible. Importantly, they were independently validated by EDRN BRL laboratory. A second step EDRN validation with bigger cohort (n=100) is currently underway prior to a multi-center validation. No significant financial relationships to disclose.
Partial nephrectomy in the setting of metastatic renal cell carcinoma.
Authors: Kara Babaian, Surena F. Matin, Pheroze Tamboli, Nizar M. Tannir, Eric Jonasch, Christopher G. Wood, Jose A. Karam
Journal: Journal of Clinical Oncology (2013)

440 Background: Up to one-third of patients with renal cell carcinoma present with metastatic disease (mRCC). Cytoreductive nephrectomy remains the standard of care for appropriately selected patients. However, cytoreductive nephrectomy is not always practical. We sought to identify the indications and outcomes for partial nephrectomy (PN) in our cohort of patients with mRCC, with particular attention to different PN subgroups. Methods: Using our institutional database, 30 patients with mRCC who underwent PN between 1996 and 2011 were identified. Demographic, clinical, and pathologic variables were collected. Non-parametric statistics and log-rank tests were used. Cancer specific survival (CSS) was estimated using Kaplan-Meier method according to presentation, tumor size, and presence of metastatic disease, from the time of PN to last follow-up or death. Results: The median age at PN was 57 years (range 32-84). 8 patients presented with bilateral synchronous renal masses; 17 presented with a metachronous contralateral renal mass; and 5 presented with a unilateral renal mass (including 3 in a solitary kidney). Median follow-up after PN was 32 months (range 1-184). Overall, 23 patients (77%) died of disease at a median of 27 months (range 7-86) after PN. Patients who underwent PN for a metachronous contralateral renal mass had a median CSS of 61 months compared to those with bilateral synchronous or unilateral renal masses (CSS 26.5 months, HR 2.98, p =.012 and CSS 31, HR 2.12, p =.069, respectively). Patients who underwent PN for a renal mass ≤4cm and &gt;4cm had a median CSS of 42 and 26.5 months, respectively (HR 2.49, p =.037). Median CSS for patients with and without metastatic disease at original diagnosis was 27 and 61 months, respectively (HR 2.85, p =.013). In this study, patients who became M0 after metastasectomy did not have improved CSS compared to patients who did not (42 and 32 months, p =0.152). Conclusions: Our findings suggest that the burden of disease at initial diagnosis, timing of presentation of the PN index lesion, and the size of the renal mass at PN play an important role in survival. These factors should be taken into consideration when determining which patients would benefit from PN in the setting of mRCC.
Optimizing outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC) through continuous inhibition of HER2 activity: A single institution study.
Authors: P. Fedele, L. Orlando, P. Schiavone, N. Calvani, A. Marino, A. Nacci, F. Sponziello, E. Mazzoni, P. Rizzo, S. Cinieri
Journal: Journal of Clinical Oncology (2011)

e11067 Background: Anti-HER2 therapies are effective in HER2+ breast cancer; even if resistance occurs, continued HER2 inhibition is required for antitumor effect. There are no definitive data on the clinical benefit of continued trastuzumab (T) beyond progression in MBC and the optimal duration of T in pts with long-term control of disease. This study explores outcomes of MBC pts treated with T in multiple sequential lines. Methods: From 2001 to 2009 we evaluated OS and cardiac toxicity in 50 pts with HER2+ (ASCO/CAP criteria) MBC who received T-based therapy for ≥ 12 months. OS was measured from the beginning of T-based CT to the last follow up visit or death. Cardiac event was any decline in LVEF by >10% from baseline or drop to <50%, III/IV NYHA CHF, new onset angina myocardial infarction, significant arrhytmias or sudden cardiac death. Results: Median age was 59 (33-79), visceral disease in 60% and multiple site in 34%; 8 (16%) pts developed brain metastasis during T. All had overexpression of HER2 by IHC, FISH was centrally assessed in 78% and not amplified in 8%. T was administered for a median duration of 23 months (12-120). All pts received a median of 2 CT regimens (1-8); 9 out of 25 pts with endocrine responsive disease received endocrine therapy plus T after at least 1 CT regimen; 20 pts (40%) experienced CR and received T alone as maintenance for a median duration of 9 months (3-46); 23 (46%) pts received lapatinib, when the drug was licensed in Italy, after failure of at least two T-based CT lines. Median OS was 34 months (12-120). There were 3 cardiac events (6%) and consisted in asymptomatic decrease in LVEF to less than 50%; T-based CT was interrupted in 1 patient because of LVEF decrease to ≤ 40%. Conclusions: T in multiple sequential lines demonstrated highly favorable outcomes in MBC pts. Overall the incidence of cardiac dysfunction was low.
Adult diffuse large B-cell lymphoma (DLBCL) of the testis: Analysis of the Surveillance, Epidemiology and End Results (SEER) database from 1980–2004
Authors: J. D. Gundrum, M. A. Mathiason, R. S. Go, D. B. Moore
Journal: Journal of Clinical Oncology (2008)

19524 Background: We examined the trends in the incidence and overall survival (OS), as well as predictive factors in a population-based cohort of adult patients with testicular DLBCL. Methods: We used histology codes 9675, 9680, and 9684 with testis as the primary site to identify all cases found in the entire SEER database from 1980–2004. For incidence rates, age-adjusted calculations were expressed per 100,000 persons in 5 year increments and limited to the SEER 9 database. OS of testicular DLBCL was compared to male nodal DLBCL using all cases from 1980–2004. Results: There were 707 patients with a mean age at diagnosis of 68 years (range, 21–98). The stage distribution was I-II (73.8%), III-IV (18.8%), and unknown (7.4%). Isolated involvement of the right or left testis was nearly equal (47.5% v 45.4%) while the remaining were either bilateral (6.4%) or unspecified (0.7%). The race composition included white (81.8%), Asian (8.1%), Hispanic (6.4%), black (3.3%), and Alaskan/Native American (0.4%). The incidence rate increased from 0.062 per 100,000 persons in 1980–84 to 0.091 per 100,000 persons in 2000–04 (p=0.019). OS was higher for testicular DLBCL over the first 10 years than for nodal DLBCL. Median OS was 4.4 years for testicular DLBCL while 1.9 years for nodal DLBCL (p<0.001). The 3 and 5-year OS rates for testicular DLBCL were 57.4% and 45.0%, respectively. Univariate analysis showed lower OS for patients over age 60 (p<0.001), stage III-IV (p<0.001), left testicular involvement only (p=0.017), treatment without surgery and radiation (p< 0.001), and diagnosis prior to 2001 (p=0.025), when rituximab became standard of care. Race was not predictive of OS. After multivariate analysis, all variables retained significance except for year of diagnosis, which had a borderline significant value (p= 0.052). Conclusions: The incidence of testicular DLBCL has increased over time. There is a trend towards better survival in recent years, as use of rituximab increased. However, longer follow-up is needed to obtain a more thorough comparison of survival. Testicular DLBCL has better OS than nodal DLBCL over the first 10 years. No significant financial relationships to disclose.
An analysis of sera-based microRNAs as biomarkers of recurrence in melanoma.
Authors: E. B. Friedman, S. Shang, E. Vega-Saenz de Miera, M. W. Ma, R. S. Berman, R. L. Shapiro, A. C. Pavlick, E. Hernando, Y. Shao, I. Osman
Journal: Journal of Clinical Oncology (2011)

8513 Background: Identification of primary localized melanoma patients at high risk for the development of metastatic disease is critical for informed decisions on patients’ management. Given the advantage of non-invasive collection of blood and evidence of microRNA (miRNA) dysregulation in cancer and stability in serum, we hypothesize that the differential expression of miRNA in the serum could be developed as sensitive and specific marker of metastatic potential of primary melanoma. Methods: Patients prospectively enrolled at New York University Medical Center with sera drawn at the time of primary diagnosis and ≥3 years follow-up were identified for training and validation testing. miRNAs were selected based on: 1) microarray tissue-based data, 2) association with melanoma progression in preclinical models, 3) differential expression in melanoma vs. nevi, and 4) evidence of dysregulation in other cancers. Using RT-qPCR analysis, levels of 16 miRNAs were quantified in the sera of primary melanoma patients and 3 control groups (healthy volunteers, non-melanoma cancers, and systemic inflammatory disease). Raw Ct values were normalized to miR-16 as an internal control. Results: Four miRNAs (miR-15b, -182, -221, -324.3p) were found to be differentially expressed in melanoma patients (n=94) compared to the controls (n=55) (p-values <0.001, two sample t- tests). Logistic regression modeling and the associated ROC analyses found 2 miRNAs (miR-182, -221) able to discriminate melanoma from controls with an AUC= 0.86 (95% CI, 0.80-0.92). Among melanoma patients, miR-182 was upregulated in melanoma patients who metastasized vs. those who did not (31 vs. 63 respectively, p-value<0.03) using a two-sided t-test. A multiple logistic regression model with miRNAs as covariates indicated that miR-15b, miR-182, and miR-221 are statistically significant predictors of melanoma metastasis (p-values <0.04). Conclusions: Our data support the potential of serum miRNAs as non-invasive prognostic biomarkers in melanoma. Longitudinal testing with repeated sampling and integration of clinical data into a predictive model will further define its clinical utility.
Differences in self-care behaviors by varying levels of caregiving intensity, performance, and well-being among family caregivers of patients with high-mortality cancer.
Authors: J Nicholas Dionne-Odom, Wendy Demark-Wahnefried, Richard A. Taylor, Gabrielle Betty Rocque, Andres Azuero, Aras Acemgil, Michelle Y Martin, Meka Astin, Deborah Ejem, Elizabeth Ann Kvale, Karen Heaton, Maria Pisu, Edward E. Partridge, Marie Bakitas
Journal: Journal of Clinical Oncology (2016)

239 Background: Family caregivers of high-mortality cancer patients perform vital tasks that deter from their own self-care. We aimed to determine differences in self-care behaviors by varying levels of caregiving intensity, well-being, and performance. Methods: Cross-sectional survey conducted in community settings of 8 cancer centers in AL, FL, and TN. Two-hundred and ninety-four family caregivers of Medicare beneficiaries diagnosed with pancreatic, lung, brain, ovarian, head &amp; neck, hematologic, or stage IV cancer completed measures of self-care behaviors, including health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, stress management, and sleep; anxiety and depression; health-related quality of life (HRQoL); caregiver competence and preparedness; and decision-making self-efficacy. Results: Caregivers averaged 66 years and were mostly female (72.8%), white (91.2%), Protestant (76.2%), retired (54.4%) and patients’ spouse/partner (60.2%). Approximately half were rural-dwellers (46.9%) and had incomes &lt;$50,000 (53.8%). The majority provided support 6-7 days per week (71%) for &gt; 1 year (68%). Lower self-care behavior scores were associated with longer durations, higher hours, and more days/week of caregiving and with fair or poor patient health. Worse caregiver anxiety, depression, and mental HRQoL scores were significantly associated with lower scores in every self-care subdomain (all ps &lt; .05). Nearly a quarter of respondents reported high depression scores (23%) and 34% reported borderline or high anxiety scores. Caregivers with lower competence, preparedness, and decision-making efficacy had lower spiritual growth, interpersonal relation, and stress management scores. Conclusions: Higher caregiving intensity is associated with worse caregiver self-care. Poorer self-care in all domains is associated with worse caregiver well-being. Interventions to optimize caregiver wellbeing should target all self-care behaviors and to optimize caregiver performance should target spiritual growth, interpersonal relation, and stress management self-care behaviors.
Role of molecular factors in renal cell carcinoma: a tissue array-analysis
Authors: L. M. Antón Aparicio, V. Medina Villaamil, L. Valbuena Ruvira, J. L. Rey Sanjurjo, S. M. Díaz Prado, M. Valladares Ayerbes, G. Aparicio Gallego, I. Santamarina Caínzos, M. Haz Conde, E. Grande Pulido
Journal: Journal of Clinical Oncology (2008)

16056 Background: The clinical behaviour of Renal Cell Carcinoma (RCC) is often unpredictable. Alterations in cell signalling are the most common types of defects in kidney cancer contributing to its development and/or progression. Understanding the molecular characteristics and heterogeneity of RCC will contribute to identify, validate and clinically test molecular therapeutic targets and biomarkers of disease activity. Our aim is to assess a relationship between molecular factors for invasion (cKit, TGF,α PDGFR-β), apoptosis (Bcl- 2) and angiogenesis (HIF1-α, Flk-1, VEGF, VHL) with clinical/anatomopathological features of the patients with RCC. Methods: This study investigated the pattern of protein expression in RCC specimens using tissue-array (TA) technology. We retrospectively analized 46 paraffin-embedded RCC samples: 1 chromophobe RCC (CRCC), 5 papillary RCC (PRCC) and 40 clear cell RCC (CCRCC). 6x8 matrix was designed to construct TA blocks. Immunohistochemical (IHC) reaction was visualized by the Dako EnVision system and diaminobenzidine following manufacturer´s instructions. Results: The IHC data were correlated with different pathological parameters: tumor localization, renal pelvis invasion, vein invasion, lymph vessel invasion, breaking capsule, histological type, Furhman grade, hilio invasion and tumor stage. By means of non-parametric statistics (U-Mann Withney test) we tested: -Bcl-2 IHC staining was significantly higher in those patients without renal pelvis invasion with a significant level of p=0,021;-cKit immunoreactivity was significantly higher in those cases with breaking capsule (p=0,014). By means of non-parametric statistics (Kruskal-Wallis test) we could appreciate:-Flk-1 and VEGF expression was higher in PRCC than in the other ones with a significant level of p=0,005 and p=0,036 respectively; -Bcl-2 showed more immunopositivity in patients without metastasis (p=0,001). Conclusions: These results indicate that Flk-1 and VEGF may be useful in the future differential diagnosis in RCC. The expression of Bcl-2 might have potential use as strong prognostic factor. Much larger RCC patient series are needed to validate the findings of our approach. S. Díaz Prado is beneficiary of an Isidro Parga Pondal contract from Xunta de Galicia (Spain). No significant financial relationships to disclose.